Genentech withdrew its psoriasis drug Raptiva from the market yesterday, citing the risk of developing progressive multifocal leukoencephalopathy (PML), a rare, often fatal brain infection. The drug will be phased out by June 8 of this year, according to a statement by the US Food and Drug Administration (FDA). The decision comes after Genentech reported a fourth case of PML diagnosed in a 47 year old man in Germany in February, and a subsequent warning by the FDA. Three other people taking Rap
 |
In mammals, intracellular clocks begin to tick within days of fertilization.
View this Issue
Learn how mastering the ins and outs of PCR can accelerate workflows and improve data.
Molecular detection technologies help scientists rapidly and reliably find and address ever-evolving pathogens with optimal accuracy and sensitivity.
Discover the key features to consider when selecting a new refrigerator or freezer
In this webinar, Kevin J. Tracey and Lawrence Steinman will discuss how researchers study the immunology of the brain and its roles in health and disease.
Integration of the NVIDIA BioNeMo platform enhances AI capabilities across the drug discovery lifecycle
DeNovix introduces the Helium 1 µL Spectrophotometer, a new affordable nanovolume spectrophotometer in the DS-Series Quantification Range.
Olink® Reveal is an NGS-based proteomics solution offering high-throughput biomarker analysis with minimal hands-on time. Requiring just 4 µL of sample, it enables deep proteome profiling in 1.5 days, leveraging existing NGS infrastructure for efficient and cost-effective protein analysis.
Zymo Research Corp., a leader in biotechnology and microbiome research solutions, proudly announces the launch of its new Quick-16S™ Full-Length Library Prep Kit.
